Odorant Mixture Discrimination for Mood Depression Diagnosis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for major depressive disorders, particularly those involving mood depression, often fail to adequately respond to SSRI/SNRI medications, with 60% of episodes not responding adequately and 20-30% being resistant, and there is a lack of understanding about the role of odor impairment in these conditions.
Innovation Solution
The development of mixtures comprising at least two different odorants in varying proportions, which are used to assess olfactory discrimination capacity, providing a diagnostic indicator for mood depression and treatment resistance, as these mixtures are designed to differentiate between proportions of odorants, correlating with the severity of the disorder and treatment response.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If SSRI/SNRI medications are used to treat major depressive disorders, then some patients experience symptom relief, but 60% of episodes do not respond adequately and 20-30% are resistant to treatment
Solution Approach 1:
The patent changes the diagnostic parameter from traditional clinical assessments to olfactory discrimination testing. By measuring the ability to distinguish between different odorant mixtures, the patent identifies a new biomarker that correlates with treatment response, enabling better prediction of which patients will respond to SSRI/SNRI medications versus requiring alternative treatments.
Solution Approach 2:
The patent introduces olfactory discrimination capacity as an intermediary biomarker that mediates between the patient's neurological state and treatment outcome prediction. This intermediary measure provides objective data about central nervous system function that correlates with antidepressant response, bridging the gap between clinical symptoms and treatment efficacy.
2Loss of information
If traditional clinical diagnosis methods are used for mood depression, then treatment decisions can be made, but there is a lack of understanding about the role of odor impairment and no objective biomarker for treatment resistance
Solution Approach 1:
The patent replaces subjective clinical assessment mechanisms with an objective olfactory discrimination testing system. Instead of relying on patient self-reporting and clinician judgment, the patent uses a standardized test involving odorant mixture discrimination that provides quantifiable, objective data about central nervous system function and treatment response prediction.
Solution Approach 2:
The patent introduces olfactory discrimination capacity as an intermediary biomarker that mediates between the patient's neurological state and treatment outcome prediction. This intermediary measure provides objective data about central nervous system function that correlates with antidepressant response, bridging the gap between clinical symptoms and treatment efficacy.
3Measurement precision
If olfactory sensitivity is measured using detection tests with single odorants, then threshold values can be obtained, but olfactory discrimination capacity in depressed subjects is not adequately assessed
Solution Approach 1:
The patent segments the olfactory assessment into two distinct components: detection threshold testing with single odorants and discrimination capacity testing with odorant mixtures. By separating these functions, the patent identifies that while detection sensitivity may be preserved, discrimination capacity is specifically impaired in depressed patients, providing more nuanced diagnostic information.
Solution Approach 2:
The patent adds a new dimension to olfactory assessment by moving from univariate detection threshold measurement to bivariate discrimination capacity evaluation. By introducing mixture composition analysis as an additional assessment dimension, the patent captures information about central nervous system function that single-odorant tests cannot provide.
Data Source
AI summary
A kit of two compositions comprising the same odorants in mixtures of different proportions is used for the measurement of olfactory discrimination capacity in subjects affected by a psychiatric disorder or disease involving mood disturbance, more particularly mood depression.